Vascular endothelial growth factor in articular cartilage of healthy and osteoarthritic human knee joints

D Pfander, D Körtje, R Zimmermann, G Weseloh, T Kirsch, M Gesslein, T Cramer, B Swoboda

Abstract

Objective—To determine the levels of vascular endothelial growth factor (VEGF) mRNA and protein expression in normal and osteoarthritic (OA) human articular cartilage, and whether VEGF expression alters during the progression of OA.

Methods—Sections from normal and OA human knee cartilage were immunostained with a polyclonal antibody recognising VEGF. In addition, total RNA was isolated from normal and osteoarthritic human knee cartilage and analysed by reverse transcriptase-polymerase chain reaction (RT-PCR) for VEGF mRNA expression.

Results—VEGF was found to be present in normal and OA human knee cartilage in all cartilage layers. A significant increase of VEGF immunopositive chondrocytes to up to 82% was detected in severe OA cartilage compared with normal articular cartilage (~56% of immunopositive chondrocytes). RT-PCR analysis showed the expression of VEGF also on the mRNA level.

Conclusions—VEGF is expressed by articular chondrocytes in normal and OA human knee cartilage. The percentage of VEGF immunopositive chondrocytes significantly increases in late stages of the disease. The VEGF transcript levels encoding all four isoforms shows a big variability in samples from different donors, suggesting a distinct regulation of the expression of the four VEGF isoforms in normal and OA cartilage.

(Ann Rheum Dis 2001;60:1070–1073)

Osteoarthritis (OA) is a multifactorial disease of diarthrodial joints, resulting in a loss of articular cartilage, a remodelling of subchondral bone, and inflammatory reactions of the synovial.1 The key event in OA cartilage is the failure of chondrocytes to compensate for the enzymatically and mechanically induced matrix degradation.2 3

Vascular endothelial growth factor (VEGF) was found to be present in the hypertrophic zone of the embryonic mouse growth plate cartilage. Evidence was provided that VEGF produced by hypertrophic chondrocytes stimulates the angiogenesis in growth plate cartilage.4 Four different VEGF isoforms, consisting of 121, 165, 189, and 206 amino acids, respectively, result from alternative splicing of a single gene product.5 In addition, four VEGF receptors have been characterised.6 Previous studies have shown an increased production of VEGF under hypoxic conditions and in response to mechanical forces.7 8 Interestingly, altered oxygen pressures and mechanical forces have been demonstrated in articular cartilage under pathological conditions, such as OA.9 10 Thus, possibly, an increased expression of VEGF occurs in OA cartilage, leading to the observed blood capillary invasion from subchondral bone into articular cartilage. To test this hypothesis we considered the following questions: (a) Do articular chondrocytes in vivo express VEGF? (b) Does VEGF expression correlate with the severity of OA?

Materials and methods

SAMPLE ACQUISITION, TISSUE PREPARATION, AND HISTOLOGICAL/HISTOCHEMICAL GRADING

Twenty seven OA human cartilage samples from 26 different donors were obtained from patients undergoing total knee replacement. The clinical data were carefully reviewed to exclude any forms of secondary OA and inflammatory joint diseases. Additionally, six healthy samples without any signs of OA were obtained from four donors within 12–24 hours after death and from one patient who underwent an amputation. Specimens were fixed, decalcified, and embedded in paraffin as described.11 After sectioning, specimens were stained with safranin O, scored according to Mankin, and divided into normal, mild OA, moderate OA, and severe OA as described.11 12

IMMUNOHISTOCHEMISTRY

After deparaffinisation, non-specific binding sites were blocked by incubation with 5% bovine serum albumin in phosphate buffered saline pH 7.4 for 30 minutes. Then sections were incubated overnight at 4°C with a polyclonal antibody against VEGF (IgG) in a dilution of 1:100 (Santa Cruz Biotechnology Inc, USA). Control cartilage sections were incubated with non-immune rabbit IgGs (Santa Cruz Biotechnology Inc, USA). After incubation with primary antibodies, sections were treated with biotinylated donkey anti-rabbit antibodies (Dianova, Hamburg, Germany), followed by streptavidin labelled with alkaline phosphatase (Dako, Hamburg, Germany) and staining with Fast Red (Sigma, Munich, Germany). Sections were viewed under a Leica microscope. The percentage of immunopositive cells was determined by counting 100 chondrocytes twice throughout
the entire depth of cartilage under a high power field. Statistical analyses were carried out on all data points for immunopositive cells in normal articular cartilage by a non-parametric Mann-Whitney U test. Data are given as means (SD) of different donors. p Values less than 0.05 were considered significant.

RNA PREPARATION
Seventeen samples of OA cartilage were obtained from 12 patients who were undergoing a total knee replacement. Additionally, two samples with no signs of joint disease were obtained from necropsies. The tissue was frozen and shredded in liquid nitrogen. Total RNA was isolated from cartilage using the TRIZol reagent (BRLGibco, Eggenstein, Germany) and purified with the Nucleo-Spin-RNA-II-Kit (Clontech Laboratories, Palo Alto, USA), as recommended by the manufacture. Total RNA yields were calculated by measurement of the absorbance at 260 nm (UltraspexIII, LKB).

REVERSE TRANSCRIPTION (RT) AND POLYMERASE CHAIN REACTION (PCR)
Sequences of VEGF primers were designed as described by Iizuka et al. The primers used had the following sequences: 5'-CTGCTGTCTTGGGTGCATTG-3' and 5'-TTCACATCTTGGGTGCATTG-3'.

Figure 1 (A) Normal articular cartilage immunostained with antibodies against VEGF, showing positive (arrowheads) and negative chondrocytes (arrows) in all cartilage layers; Mankin score 1. VEGF positive and negative chondrocytes from the deep zone are shown in close up (inset). (B) Severe OA cartilage with a strong immunostaining of the chondrocyte clusters next to the surface (arrowheads) and also VEGF positive chondrocytes throughout the remaining deep zone (arrows); Mankin score 11. Positive chondrocytes within a cluster are displayed in close up (inset). (C) A slide adjacent to (B) incubated with non-immune rabbit serum as negative control. Arrows indicate negative chondrocytes. Bar represents: (A) 200 µm; (B) 100 µm; and (C) 60 µm.
TTGTGTGCTGTAG-3’. The resulting PCR product was 378 bp. RNA 160 ng was converted to complementary DNA (cDNA) by incubation with specific reverse primers for VEGF. The RT reaction was performed using the first strand cDNA synthesis kit (Roche Diagnostics GmbH, Mannheim, Germany) in a 20 µl reaction mixture (5 mM MgCl2, 1 mM dNTP mix, RT buffer, inhibitor, and 20 U AMV reverse transcriptase) for 10 minutes at 25°C, followed by incubation at 42°C for 60 minutes, and enzyme denaturation at 95°C for five minutes. cDNA 2 µl was amplified by PCR through 29 or 35 cycles (denaturation at 95°C for 30 seconds, annealing at 60°C for 30 seconds, and elongation at 72°C for 45 seconds) using taq-DNA-polymerase (Roche Diagnostics GmbH, Mannheim, Germany) and the specific upstream and downstream primers (0.4 µM) in a 25 µl reaction mixture containing 2 mM MgCl2 and 0.2 mM Nucleotide-Mix (Boehringer, Mannheim, Germany). The PCR was terminated by an elongation step for 10 minutes at 72°C. To estimate the amount of VEGF mRNA, GAPDH mRNA levels were determined. Therefore, RNA was transcribed into single complementary DNA using AMV reverse transcriptase (Boehringer, Mannheim, Germany) and oligo-p(dT)15 primer, according to the manufacturers protocol. GAPDH primers used in the amplification reactions had the following sequences 5’-CGAGATCCCTCCAA TCAA-3’ and 5’-TGTGGTCATGAGTC CCCA-3’, resulting in a product of 294 bp. cDNA was amplified through 35 cycles. PCR products were separated on 1.5% agarose gels and visualised by ethidium bromide staining.

**Results**

Expression of VEGF on the protein level in normal and OA human articular cartilage samples was determined by immunohistochemistry with antibodies recognising predominantly the 165 amino acid long VEGF isoform. Chondrocytes immunopositive for VEGF were detected in all layers of normal and OA cartilage (fig 1A). There was a significant increase in the number of VEGF positive chondrocytes in cartilage samples of severe OA. Especially, enlarged clustered chondrocytes next to the cartilage surface showed strong immunostaining for VEGF (fig 1B). Slides incubated with non-immune rabbit IgGs showed no staining (fig 1C). In mild and moderate OA cartilage a slight, but non-significant reduction of VEGF stained chondrocytes was detected. This decrease was mainly due to a smaller number of VEGF positive chondrocytes in the deep zone.

To determine whether VEGF immunopositive chondrocytes express VEGF also on the mRNA level, we isolated total RNA from normal and OA human cartilage samples and analysed VEGF expression by relative quantitative RT-PCR analysis. The primers used for PCR analysis detected all four isoforms of VEGF. The levels of VEGF mRNA expression in healthy and OA cartilage varied significantly between samples from different donors without a clear correlation with OA progression (fig 1B). Table 1 summarises the results of VEGF immunostaining.

**Table 1** Summarised results of vascular endothelial growth factor (VEGF) immunostaining

<table>
<thead>
<tr>
<th>Percentage of VEGF positive chondrocytes</th>
<th>Normal cartilage samples (n=6)</th>
<th>Mild OA samples (n=8)</th>
<th>Moderate OA samples (n=9)</th>
<th>Severe OA samples (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>56 (13.0)</td>
<td>51.4 (11.2)</td>
<td>53.2 (12.8)</td>
<td>82.2* (6.9)</td>
</tr>
</tbody>
</table>

Percentages of VEGF positive chondrocytes throughout the entire depth of the specimens. In each specimen 100 chondrocytes were counted twice using a high power magnification field. Percentage of VEGF immunostained chondrocytes are given as means (SD).

*p<0.05 (versus percentage of positive chondrocytes in normal cartilage).
**Discussion**

The results of this study show for the first time that VEGF is expressed on the mRNA and protein level by chondrocytes of normal and OA human articular knee cartilage. The percentage of VEGF immunopositive chondrocytes significantly increased in severe OA cartilage. However, RT-PCR analysis disclosed a great variability in VEGF mRNA levels between cartilage samples from various donors without a clear correlation with an increased level of expression in severe OA cartilage. The discrepancy between increased immunostaining for VEGF and unaltered VEGF mRNA levels in normal and severe OA cartilage may be explained by the fact that the primers used for PCR detected all four VEGF isoforms, whereas the antibody used for immunostaining predominantly recognised the 165 amino acid long isoform of VEGF. Therefore, the differences of protein and RNA levels in normal and OA articular cartilage might reflect differential regulation of the various four isoforms of VEGF during the progression of OA.

VEGF has been found to induce capillary growth in a number of physiological and pathological conditions, including angiogenesis in growth plate cartilage and tumours. Furthermore, it has been suggested that VEGF contributes to apoptosis of hypertrophic growth plate chondrocytes by inducing the liberation of pro-apoptotic factor from blood vessels. Interestingly, in late stages of OA, blood vessel invasion from the subchondral bone into the articular cartilage has been found. Reversal regulation of the various four isoforms on invasion of blood vessels from subchondral bone, and subsequent apoptosis of chondrocytes during the progression of OA.

VEGF has been found to induce capillary growth in a number of physiological and pathological conditions, including angiogenesis in growth plate cartilage and tumours. Furthermore, it has been suggested that VEGF contributes to apoptosis of hypertrophic growth plate chondrocytes by inducing the liberation of pro-apoptotic factor from blood vessels. Interestingly, in late stages of OA, blood vessel invasion from the subchondral bone into the articular cartilage has been found. Recently, we have shown that expression of thrombospondin-1 (TSP-1), a potent anti-angiogenic factor, is decreased in OA cartilage. Thus it can be speculated that disturbed maintenance of pro- and anti-angiogenic factors may lead to the observed invasion of blood vessels. As mentioned above, these ingrowing blood vessels may liberate pro-apoptotic signals into articular cartilage, leading to the described apoptotic events in OA chondrocytes.

Thus this study suggests that an altered expression of VEGFs, in combination with a possible down regulation of anti-angiogenic factors in OA cartilage, may stimulate the invasion of blood vessels from subchondral bone into articular cartilage, contributing to the progression of the disease. Future work needs to establish the exact role of VEGF in normal articular cartilage, the distinct regulation of its isoforms in OA cartilage and the effect of these isoforms on invasion of blood vessels from subchondral bone, and subsequent apoptosis of chondrocytes during the progression of OA.

Vascular endothelial growth factor in articular cartilage of healthy and osteoarthritic human knee joints

D Pfander, D Körtje, R Zimmermann, G Weseloh, T Kirsch, M Gesslein, T Cramer and B Swoboda

Ann Rheum Dis 2001 60: 1070-1073
doi: 10.1136/ard.60.11.1070

Updated information and services can be found at:
http://ard.bmj.com/content/60/11/1070

These include:

References
This article cites 9 articles, 1 of which you can access for free at:
http://ard.bmj.com/content/60/11/1070#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Immunology (including allergy) (5144)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/